ACRX - AcelRx Pharmaceuticals, Inc.
| Previous Close | 3.3600 |
| Open | 3.3500 |
| Bid | 3.3700 x 1200 |
| Ask | 3.3800 x 1000 |
| Day's Range | 3.3100 - 3.3900 |
| 52 Week Range | 1.9900 - 5.0500 |
| Volume | 772,577 |
| Avg. Volume | 2,151,219 |
| Market Cap | 266.202M |
| Beta (3Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8100 |
| Earnings Date | Oct 30, 2017 - Nov 3, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.21 |
- Investopedia•8 hours ago
Penny Stocks to Buy Using Technical Analysis for April 2019
As we near a turning of the tide in the markets, penny stocks could bounce around more quickly than usual, so traders should be extra alert.
- PR Newswire•9 days ago
AcelRx Pharmaceutical's pooled safety results for sufentanil sublingual tablets (DSUVIA) selected for presentation at 44th Annual Regional Anesthesiology & Acute Pain Medicine Meeting
REDWOOD CITY, Calif. , April 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of ACRX earnings conference call or presentation 7-Mar-19 9:30pm GMT
Q4 2018 AcelRx Pharmaceuticals Inc Earnings Call
- Zacks•17 days ago
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
- Zacks•23 days ago
AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: What Does It Mean for the Stock?
AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- PR Newswire•last month
AcelRx Pharmaceuticals to Present at Oppenheimer & Co. Inc. 29th Annual Healthcare Conference
REDWOOD CITY, Calif. , March 11, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- Motley Fool•last month
Why AcelRx Pharmaceuticals Stock Is Sinking Today
Investors wanted more good news than they got in the specialty-drug maker's fourth-quarter update.
- Zacks•last month
Here's Why Momentum Investors Will Love AcelRx Pharmaceuticals (ACRX)
Does AcelRx Pharmaceuticals (ACRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- PR Newswire•last month
AcelRx Pharmaceuticals Announces Commercial Launch of DSUVIA and Reports Fourth Quarter and Full Year 2018 Financial Results
- DSUVIA now available for use in certified medically supervised healthcare settings, with initial shipments to wholesalers completed in the second half of February 2019 - Executed contracts with Group ...
- Motley Fool•2 months ago
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.
- PR Newswire•2 months ago
AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
REDWOOD CITY, Calif. , Feb. 22, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter and annual financial ...
- ACCESSWIRE•2 months ago
Biotech Leaders to Watch This Week
HENDERSON, NV / ACCESSWIRE / February 19, 2019 / Biotechnology is coming back strong in 2019 as the iShares Nasdaq Biotechnology Index's 16% surge higher during the first month and a half of this new year ...
- ACCESSWIRE•2 months ago
4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)
CORAL GABLES, FL / ACCESSWIRE / February 19, 2019 / The success of healthcare stock market is based on whether or not companies in the healthcare industry have the ability to meet the growing demands of consumers. As a result of the advent of new technologies and product offerings in other industries, healthcare customers have come to expect the same experience from healthcare companies. ), AcelRx Pharmaceuticals Inc (ACRX), and Bio Blast Pharma Ltd (ORPN) represent four healthcare companies operating with the consumer's best interests in mind.
- Zacks•2 months ago
Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
Is (ACRX) Outperforming Other Medical Stocks This Year?
- PR Newswire•3 months ago
AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
REDWOOD CITY, Calif. , Jan. 31, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
- GlobeNewswire•3 months ago
Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster's Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services — Discovering Underlying Factors of Influence
NEW YORK, Jan. 09, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•3 months ago
AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
- Over 800 patients from AcelRx studies supporting DSUVIA™ approval were included in the pooled safety analysis - Initial dosing of 30 mcg sufentanil sublingual tablet calculated as dose-equivalent to ...
- Motley Fool•4 months ago
2 Biotech Penny Stocks to Buy Right Now
AcelRx and Novavax are two penny biotech stocks worth checking out in this latest market downturn.
- Insider Monkey•4 months ago
Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX)
Amid an overall market correction, many stocks that smart money investors were collectively bullish on tanked during the fourth quarter. Among them, Amazon and Netflix ranked among the top 30 picks and both lost around 20%. Facebook, which was the second most popular stock, lost 14% amid uncertainty regarding the interest rates and tech valuations. […]
- Zacks•4 months ago
Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options
Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.
- PR Newswire•4 months ago
AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI)
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative ...
- Motley Fool•5 months ago
3 Stocks to Hold for the Next 20 Years
When you invest in a business, you should expect to stay with it for the long haul.
- PR Newswire•5 months ago
AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
Update on DSUVIA U.S. commercialization strategy and insights from key healthcare professionals REDWOOD CITY, Calif. , Nov. 29, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), ...
- ACCESSWIRE•5 months ago
New Healthcare Trends Could Push Sector Stocks Higher
CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of ACRX earnings conference call or presentation 5-Nov-18 1:30pm GMT
Q3 2018 AcelRx Pharmaceuticals Inc Earnings Call
